Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Patients with pulmonary arterial hypertension were randomly assigned to receive sotatercept at a dose of 0.3 mg per kilogram or 0.7 mg per kilogram or placebo, in addition to standard therapy. At 24 weeks, both sotatercept groups had a greater reduction in pulmonary vascular resistance than the plac...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-04, Vol.384 (13), p.1204-1215
Hauptverfasser:	Humbert, Marc, McLaughlin, Vallerie, Gibbs, J. Simon R, Gomberg-Maitland, Mardi, Hoeper, Marius M, Preston, Ioana R, Souza, Rogerio, Waxman, Aaron, Escribano Subias, Pilar, Feldman, Jeremy, Meyer, Gisela, Montani, David, Olsson, Karen M, Manimaran, Solaiappan, Barnes, Jennifer, Linde, Peter G, de Oliveira Pena, Janethe, Badesch, David B
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Body weight Brain natriuretic peptide Cardiology and cardiovascular system Confidence intervals Dose-Response Relationship Dose-Response Relationship, Drug Double-Blind Method Exercise Tolerance Exercise Tolerance - drug effects Female Fusion protein General & Internal Medicine Hemoglobin Human health and pathology Humans Hypertension Injections Injections, Subcutaneous International organizations Intubation Laboratories Least-Square Analysis Least-Squares Analysis Life Sciences Life Sciences & Biomedicine Long bone Male Medicine, General & Internal Middle Aged Mutation Natriuretic Peptide Natriuretic Peptide, Brain - blood Peptide Fragments Peptide Fragments - blood Pharmaceutical sciences Pharmacology Placebos Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension - blood Pulmonary Arterial Hypertension - drug therapy Pulmonary Arterial Hypertension - physiopathology Pulmonary arteries Pulmonary hypertension Pulmonology and respiratory tract Recombinant Fusion Proteins Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - pharmacology Recombinant Fusion Proteins - therapeutic use School dropouts Science & Technology Signal transduction Statistical analysis Thrombocytopenia Thrombocytopenia - chemically induced Transforming Growth Factor beta Transforming Growth Factor beta - antagonists & inhibitors Vascular Resistance Vascular Resistance - drug effects Veins & arteries Walk Test
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with pulmonary arterial hypertension were randomly assigned to receive sotatercept at a dose of 0.3 mg per kilogram or 0.7 mg per kilogram or placebo, in addition to standard therapy. At 24 weeks, both sotatercept groups had a greater reduction in pulmonary vascular resistance than the placebo group.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2024277